In Kawasaki disease (KD), thrombocytosis is commonly found in the subacute phase. However, the exact significance of thrombocytosis in the acute phase of KD is unclear. To evaluate serum platelet counts in patients during the acute phase of KD and assess the clinical outcomes according to the degree of thrombocytosis, we collected data of KD patients between 2009 and 2017. A total of 505 patients with KD were enrolled, and 249 (49.3%) patients had thrombocytosis, including mild (69.5%), moderate (21.7%), severe (4.8%), and extreme (4.0%) thrombocytosis. Correlation analysis revealed a positive correlation between the maximum platelet count and admission duration (r = 0.359, p < 0.001) and fever duration (r = 0.204, p < 0.001). The maximum platelet count was significantly higher in IVIG non-responders than that in IVIG responders (629 ± 201 × 109/L vs. 499 ± 154 × 109/L, p < 0.001), and in patients with coronary artery dilatation (CAD) than in those without CAD (602 ± 201 × 109/L vs. 512 ± 164 × 109/L, p < 0.001).
Conclusion: Thrombocytosis in acute phase KD was associated with poor clinical outcomes such as IVIG non-responsiveness, CAD, and prolonged admission and fever durations.
What is Known:|
• Thrombocytopenia in the acute phase of KD is related to non-responsiveness to IVIG and the risk of coronary artery dilatation.
• The exact significance of thrombocytosis in the acute phase of KD as a benign phenomenon or a signal of poor outcome of KD is unclear.
What is New:|
• Thrombocytosis in acute phase KD was associated with poor clinical outcomes such as IVIG non-responsiveness, CAD, and prolonged admission and fever durations.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Coronary artery dilatation
Erythrocyte sedimentation rate
Macrophage activation syndrome
Receiver operating characteristic
White blood cell
McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, Baker AL, Jackson MA, Takahashi M, Shah PB, Kobayashi T, Wu MH, Saji TT, Pahl E, American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention (2017) Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 135:e927–e999
Tanoshima R, Hashimoto R, Suzuki T, Ishiguro A, Kobayashi T (2019) Effectiveness of antiplatelet therapy for Kawasaki disease: a systematic review. Eur J Pediatr 178:947–955
Arora K, Guleria S, Jindal AK, Rawat A, Singh S (2020) Platelets in Kawasaki disease: is this only a numbers game or something beyond? Genes Dis 7:62–66
Nofech-Mozes Y, Garty BZ (2003) Thrombocytopenia in Kawasaki disease: a risk factor for the development of coronary artery aneurysms. Pediatr Hematol Oncol 20:597–601
Rigante D, Andreozzi L, Fastiggi M, Bracci B, Natale MF, Esposito S (2016) Critical overview of the risk scoring systems to predict non-responsiveness to intravenous immunoglobulin in Kawasaki syndrome. Int J Mol Sci 17:278
Sutor AH (1995) Thrombocytosis in childhood. Semin Thromb Hemost 21:330–339
Dame C, Sutor AH (2005) Primary and secondary thrombocytosis in childhood. Br J Haematol 129:165–177
Newburger JW (2000) Kawasaki disease: who is at risk? J Pediatr 137:149–152
Tremoulet AH, Best BM, Song S, Wang S, Corinaldesi E, Eichenfield JR, Martin DD, Newburger JW, Burns JC (2008) Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 153:117–121
Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, Kobayashi T, Morikawa A (2006) Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 113:2606–2612
García-Pavón S, Yamazaki-Nakashimada MA, Báez M, Borjas-Aguilar KL, Murata C (2017) Kawasaki disease complicated with macrophage activation syndrome: a systematic review. J Pediatr Hematol Oncol 39:445–451
Latino GA, Manlhiot C, Yeung RS, Chahal N, McCrindle BW (2010) Macrophage activation syndrome in the acute phase of Kawasaki disease. J Pediatr Hematol Oncol 32:527–531
Burns JC, Glode MP, Clarke SH, Wiggins J Jr (1984) Coagulopathy and platelet activation in Kawasaki syndrome: identification of patients at high risk for development of artery aneurysms. J Pediatr 105:206–211
Lee KY, Rhim JW, Kang JH (2012) Kawasaki disease: laboratory findings and an immunopathogenesis on the premise of a “protein homeostasis system”. Yonsei Med J 53:262–275
Lee KY, Han JW, Hong JH, Lee HS, Lee JS, Whang KT (2004) Inflammatory processes in Kawasaki disease reach their peak at the sixth day of fever onset: laboratory profiles according to duration of fever. J Korean Med Sci 19:501–504
Jin J, Wang J, Lu Y, Fan Z, Huang N, Ma L, Yu H (2019) Platelet-derived microparticles: a new index of monitoring platelet activation and inflammation in Kawasaki disease. Indian J Pediatr 86:250–255
Wei M, Huang M, Chen S, Huang G, Huang M, Qiu D, Guo Z, Jiang J, Zhou X, Yu Q, Guo Y, Fu L, Gao W, Li F (2015) A multicenter study of intravenous immunoglobulin non-response in Kawasaki disease. Pediatr Cardiol 36:1166–1172
Levin M, Holland PC, Nokes TJ, Novelli V, Mola M, Levinsky RJ, Dillon MJ, Barratt TM, Marshall WC (1985) Platelet immune complex interaction in pathogenesis of Kawasaki disease and childhood polyarteritis. Br Med J Clin Res Ed 290:1456–1460
Kim JJ, Hong YM, Yun SW, Han MK, Lee KY, Song MS et al (2012) Assessment of risk factors for Korean children with Kawasaki disease. Pediatr Cardiol 33:513–520
Kim HJ, Choi EH, Lim YJ, Kil HR (2017) The usefulness of platelet-derived microparticle as biomarker of antiplatelet therapy in Kawasaki disease. J Korean Med Sci 32:1147–1153
This study is a retrospective and observational study and does not contain any studies with human participants or animals. This study was approved by the institutional review board of the Keimyung University Dongsan Medical Center (approval number: 2019-07-019).
Consent to participate
Consent for publication
Conflict of interest
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Communicated by Peter de Winter
About this article
Cite this article
Park, J.H., Choi, H.J. Clinical implications of thrombocytosis in acute phase Kawasaki disease. Eur J Pediatr (2021). https://doi.org/10.1007/s00431-021-03966-8
- Kawasaki disease